Summary: The Centers for Medicare & Medicaid Services modified its Next Generation Sequencing (NGS) coverage policy, effective May 15, 2026. Here's what billing teams need to do.
CMS next generation sequencing coverage policy changes affect oncology practices, pathology labs, and molecular diagnostic billers across the country. The Centers for Medicare & Medicaid Services has updated its NGS policy — the framework governing when Medicare pays for tumor profiling, hereditary cancer panels, and other genomic sequencing tests. This policy does not list specific CPT or HCPCS codes in the available policy data, but NGS billing spans a range of molecular pathology codes that your lab or practice almost certainly uses. If you bill Medicare for genomic sequencing, this change is live on May 15, 2026, and you need to know what it means before that date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Next Generation Sequencing (NGS) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Pathology, Molecular Diagnostics, Genetics, Hematology/Oncology |
| Key Action | Audit your NGS claims workflow against updated medical necessity criteria before May 15, 2026 |
CMS Next Generation Sequencing Coverage Criteria and Medical Necessity Requirements 2026
CMS has maintained an NCD-level framework for NGS since 2018, and every modification to that framework reshapes how labs and oncology practices document medical necessity. The core structure has not changed dramatically over the years — but the details matter enormously when your denial rate is on the line.
Under the existing CMS NGS coverage policy, Medicare covers NGS testing for beneficiaries with advanced cancer when specific conditions are met. The patient must have a diagnosis of recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer. The test must use a U.S. Food and Drug Administration (FDA)-approved or -cleared companion diagnostic, and the result must be used to make treatment decisions. When those boxes are checked, the coverage is real and the reimbursement follows.
The prior authorization pathway for NGS under Medicare is not a formal PA process the way you'd see with DME or some specialty drugs. Instead, CMS enforces coverage through documentation requirements baked into the medical necessity criteria. Your physicians need to show the ordering indication clearly in the record. "Advanced cancer" is not enough — the stage, the prior treatment history, and the clinical intent for using the result all have to be in the chart.
One of the persistent pressure points in NGS billing guidelines is the FDA-approval requirement. Medicare does not cover NGS tests used purely for off-label companion diagnostic purposes, and it does not cover tests where the result won't drive a treatment decision. That's not a technicality — it's the most common reason for claim denial in this category. Your ordering physicians need to document why the result matters, not just that the test was ordered.
The 2026 modification to this policy is worth watching closely because CMS has historically used these updates to tighten the definition of "advanced" cancer, expand or restrict which FDA-approved tests qualify, or adjust the documentation expectations for treating physicians. If the full text of the updated policy shifts any of these criteria, your charge capture and prior auth workflows need to reflect the change on day one — not after your first round of denials.
If you are not certain how this modification applies to your payer mix or specialty, talk to your compliance officer before May 15, 2026. NGS is a high-dollar category and CMS scrutinizes these claims.
CMS Next Generation Sequencing Exclusions and Non-Covered Indications
CMS does not cover NGS testing for early-stage cancers that do not meet the advanced or metastatic threshold. This is a firm line, not a gray area.
Germline hereditary cancer testing — panels like hereditary breast and ovarian cancer (HBOC) tests — follows a different coverage track than somatic tumor profiling. If your lab bills both, keep the workflows separate. Conflating somatic and germline indications is a fast path to a claim denial that's hard to appeal.
CMS also does not cover NGS testing when the result will not be used to guide treatment. This sounds obvious, but it surfaces regularly in practice when a physician orders a panel "for prognosis" or "for research purposes." Medicare is not paying for research. The documentation must show clinical intent to act on the result.
Tests that are not FDA-approved or FDA-cleared as companion diagnostics are not covered under the NCD framework — full stop. Some labs bill these under laboratory benefit manager carve-outs or supplemental Medicare Advantage plans, but those are separate coverage tracks. Standard Medicare fee-for-service follows the FDA-approval requirement.
Coverage Indications at a Glance
Because the available policy data does not include a full breakdown of indication-level coverage criteria from the updated document, the table below reflects the established CMS NGS coverage framework. Verify any changes against the full updated policy text at the effective date.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Advanced cancer (Stage III/IV, recurrent, relapsed, refractory, metastatic) with FDA-approved/cleared companion diagnostic | Covered | See Affected Codes section | Treatment intent must be documented; result must guide therapy selection |
| Hereditary cancer germline testing (e.g., HBOC panels) | Covered with criteria | Separate LCD framework may apply | Check your MAC's LCD — local coverage determinations vary by region |
| Early-stage cancer without advanced or metastatic designation | Not Covered | N/A | Does not meet CMS NGS medical necessity threshold |
| NGS ordered for prognosis only, without treatment decision intent | Not Covered | N/A | Lack of clinical intent to act on result is a common denial trigger |
| Non-FDA-approved NGS tests used as companion diagnostics | Not Covered | N/A | Must be FDA-approved or -cleared under NCD framework |
| NGS ordered purely for research purposes | Not Covered | N/A | Not reimbursable under Medicare fee-for-service |
CMS Next Generation Sequencing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull your NGS claim data now. Run a report on all NGS claims billed to Medicare in the past 12 months. Look at your denial rate, your top denial reasons, and your average days to reimbursement. This baseline tells you where your team is already vulnerable before the May 15, 2026 effective date. |
| 2 | Confirm every ordering physician knows the documentation standard. The number-one reason CMS NGS claims get denied is missing or insufficient documentation of medical necessity. Before May 15, 2026, send your oncology and pathology teams a one-page summary of what the chart needs to show: cancer stage, prior treatment history, FDA-approved test name, and clinical intent to use the result. Don't assume they know. |
| 3 | Verify which NGS tests in your lab or practice use FDA-approved companion diagnostics. Make a list. Any test that doesn't have FDA approval or clearance as a companion diagnostic is not covered under standard Medicare fee-for-service NGS billing guidelines — regardless of clinical utility. If you're billing those tests to Medicare, stop and talk to your compliance officer. |
| 4 | Check your Medicare Administrative Contractor's local coverage determinations. CMS sets the NCD floor, but your MAC can issue LCDs that add criteria, restrict indications, or require additional documentation. Noridian, Novitas, CGS, Palmetto — they don't all apply the NCD identically. Pull your MAC's current LCD for molecular pathology and NGS before May 15, 2026. If your MAC hasn't updated its LCD to align with the 2026 CMS modification, a new one may be coming. |
| 5 | Update your charge capture and claim scrubbing rules. If your billing system has hard-coded rules around NGS coverage criteria, update them to reflect the modified policy before May 15, 2026. A claim that went through clean last month might hit an edit next month if the criteria shifted. Your billers need to know what changed — not just that something changed. |
| 6 | Audit your Medicare Advantage NGS claims separately. MA plans are not required to follow Medicare fee-for-service coverage policy exactly. Some are more restrictive on NGS, some are less. If you bill both traditional Medicare and MA plans for NGS, treat them as two separate coverage tracks. The 2026 CMS modification applies directly to fee-for-service; your MA contracts govern the rest. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Next Generation Sequencing Under CMS NGS Policy
The available policy data for this CMS modification does not include a specific code list. This is not unusual — CMS's NCD-level NGS policy references FDA-approved tests and clinical criteria rather than enumerating individual CPT codes.
The molecular pathology codes commonly associated with NGS billing fall within the CPT 81100–81599 range, including multi-gene panel codes and proprietary laboratory analyses (PLAs) specific to FDA-approved NGS platforms. However, do not use this as a billing reference. The exact codes covered under the updated policy depend on the specific tests involved and the current CMS coverage determination.
To get the correct, current code list for NGS billing under this updated CMS policy:
- Review the full policy text at app.payerpolicy.org/p/cms/372-v2.: https://app.payerpolicy.org/p/cms/372-v2
- Check CMS's NCD database directly (NCD 90.1 governs NGS for cancer)
- Pull your MAC's current LCD for molecular pathology
- Confirm PLA codes for your specific FDA-approved NGS panels with your lab's billing team
Do not assume that the codes your team used before May 15, 2026 are still the correct codes after the modification. Verify before you bill.
Get the Full Picture for CPT 81100
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.